# CSL

Type: Company (CSL)

Source: GetYourBrief — https://getyourbrief.com/entity/csl
Canonical HTML page: https://getyourbrief.com/entity/csl

## Timeline

- **2026-03-03**: Q4 Earnings Release — Both companies scheduled to report full-year 2025 financial results.
- **2026-02-24**: Reporting Season Pressure — Difficult February reports for CSL and Sonic Healthcare extend index declines.
- **2026-02-15**: Anteris Funding — Anteris Technologies raises approximately $440 million for heart valve technology.
- **2026-01-31**: Nasdaq Biotech Peak — The index records a 30% annual gain, diverging from broader tech markets.
- **2025-12-31**: Record Funding Year — Clarity ($200m) and Mesoblast ($260m) complete significant capital raises.
- **2025-09-15**: ARCT-032 Phase 1b — Arcturus releases positive interim data for Cystic Fibrosis candidate.
- **2025-01-01**: ASX Healthcare Slump — The sector begins a calendar year decline of 25% led by major heavyweights.
- **2023-11-28**: Kostaive Approval — Japan's MHLW approves the first sa-mRNA COVID-19 vaccine.

## Recent coverage (4 stories, network-wide)

### Biotech Earnings Preview: Arcturus and Rigel Set for Pivotal Q4 Reports
2026-03-02 22:53:40 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Arcturus Therapeutics and Rigel Pharmaceuticals are preparing to report Q4 2025 results, with investors focusing on Arcturus's sa-mRNA commercialization and Rigel's path to sustained profitability. Both companies represent different archetypes of the biotech sector's shift toward commercial execution.
Full story: https://gethealthbrief.com/story/arcturus-rigel-q4-2025-earnings-preview

### Biotech’s Two-Speed Divergence: Innovation Thrives Amid Regulatory Headwinds
2026-02-25 00:13:27 · Sector: finance · Sentiment: Neutral · Impact: 6/10 · Sources: 5

The global healthcare sector is splitting into a 'two-speed' market as regulatory uncertainty under the Trump administration pressures established giants while innovative biotechs find significant capital. Despite a 25% decline in the ASX 200 healthcare index, smaller players are leveraging AI and record-setting capital raises to navigate a complex FDA landscape.
Full story: https://getfinancebrief.com/story/biotech-two-speed-market-regulatory-analysis

### Biotech’s Two-Speed Market: Innovation Defies Regulatory Headwinds
2026-02-25 00:12:53 · Sector: bio · Sentiment: Neutral · Impact: 6/10 · Sources: 5

The global biotech sector has diverged into a 'two-speed' market, where innovative drug discovery and device firms are outperforming established healthcare heavyweights. Despite regulatory uncertainty under the Trump administration and a 25% decline in the ASX 200 healthcare sector, the Nasdaq Biotech Index has surged 30%, supported by record-breaking capital raises.
Full story: https://getbiobrief.com/story/biotech-two-speed-market-analysis-2026

### Biotech’s Two-Speed Recovery: Mid-Caps Surge Amid Large-Cap Stagnation
2026-02-25 00:08:45 · Sector: health · Sentiment: Neutral · Impact: 6/10 · Sources: 5

The global healthcare sector is bifurcating as mid-cap biotech innovators outperform established heavyweights despite regulatory headwinds from the Trump administration. While the ASX 200 healthcare index fell 25% in 2025, a surge in capital raising and AI integration is fueling a resilient 'engine room' of drug discovery and device innovation.
Full story: https://gethealthbrief.com/story/biotech-long-game-two-speed-market-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.